February 14, 2008 / 1:20 PM / 10 years ago

Angiotech results hurt by royalty revenues

(In U.S. dollars)

TORONTO, Feb 14 (Reuters) - Angiotech Pharmaceuticals Inc ANP.TO ANPI.O reported a fourth-quarter loss that nearly doubled on Thursday, because of falling royalty revenues for its drug-coated stents.

Angiotech, which makes the coating for Boston Scientific Corp.’s (BSX.N) stents, said it lost $21.3 million, or 20 cents a share, during the quarter, compared with a loss of $11.7 million, or 6 cents a share, for the same period last year.

Adjusted results, which exclude noncash and nonrecurring items, showed a loss of $7.5 million, or 9 cents, for the quarter. That compares with a profit of $12 million, or 14 cents, a year earlier. ($1=$1.00 Canadian) (Reporting by Scott Anderson; Editing by Renato Andrade)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below